QuantLogix ← WST scorecard
📅 WST Earnings Preview
West Pharmaceutical Services, Inc.
Next report (est.)
November 13, 2026
Countdown
108 days
EPS growth YoY
+18.1%
Revenue growth YoY
+13.8%
Implied vs actual — last 8 reports
ReportOptions impliedActual moveMarket was
July 23, 2026 ±2.6% -0.8% over-priced
April 23, 2026 ±2.4% +12.9% under-priced
October 23, 2025 ±2.5% +10.9% under-priced
July 24, 2025 ±4.0% +22.8% under-priced
April 24, 2025 ±4.5% -3.5% over-priced
October 24, 2024 ±2.1% +15.4% under-priced
July 25, 2024 ±3.3% -14.4% under-priced
April 25, 2024 ±2.6% -4.5% under-priced
Across these reports, options implied an average ±3.0% move vs an actual average of 10.7% — the stock stayed inside the implied band 25% of the time.
Fundamentals into the print
QuarterEPS (dil.)RevenueNet income
Q2 FY2026 $2.15 $872M $154M
Q1 FY2026 $1.92 $845M $139M
Q4 FY2025 $1.82 $805M $132M
Q3 FY2025 $1.92 $805M $140M
Analyst posture
Buy / Strong Buy
20
Hold
2
Sell
0
Strong upward revisions — 28 net (vs 25 prior)
Live 5-factor engine read: Strong Buy · 66/100 Full scorecard →
Get alerted before every WST report — free Full live analysis
🤖 Pro runs a 10-agent AI debate on WST before the print — 5 analysts, bull vs bear, a risk read, and a trader's verdict. See Pro →

West Pharmaceutical Services, Inc. (WST) reports in 108 days, with the next report estimated for November 13, 2026. Across the last 8 reports, options priced an average ±3.0% earnings move while the stock actually moved 10.7% on average — the market has tended to under-price WST's earnings risk. Fundamentals into the print: EPS up 18.1% year-over-year, revenue up 13.8%. QuantLogix's live 5-factor engine currently reads WST as a strong buy at 66/100.

Implied move is derived from at-the-money option pricing; actual moves are close-to-close on report days. Next-report dates are estimates until confirmed by the company. Educational market analysis, not investment advice. Browse all signal scorecards →